Ro 496-4913/F03 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2
46	Malignant rheumatoid arthritis	2

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020338-25-BG (EUCTR)	11/05/2011	19/01/2011	A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis	A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to ev ...	Primary Progressive Multiple Sclerosis (PPMS) MedDRA version: 18.0;Level: PT;Classification code 100 ...	Product Name: ocrelizumab Product Code: Ro 496-4913/F03 INN or Proposed INN: ocrelizumab	F.Hoffmann-La Roche	NULL	Not Recruiting			Female: yes Male: yes	630	Phase 3	Portugal;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;Fra ...
2	EUCTR2010-020338-25-HU (EUCTR)	17/11/2010	29/09/2010	A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis	A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to ev ...	Primary Progressive Multiple Sclerosis (PPMS) MedDRA version: 18.0;Level: PT;Classification code 100 ...	Product Name: ocrelizumab Product Code: Ro 496-4913/F03 INN or Proposed INN: ocrelizumab	F.Hoffmann-La Roche	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	630	Phase 3	Portugal;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;Fra ...

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-005759-41-FR (EUCTR)	19/03/2008	12/02/2008	A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy ...	A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy ...	Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: ocrelizumab Product Code: RO 496-4913/F03 INN or Proposed INN: ocrelizumab Other descript ...	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	France;Spain;Germany;Italy;United Kingdom
2	EUCTR2006-005147-28-FR (EUCTR)	07/05/2007	06/03/2007	A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy ...	A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy ...	Rheumatoid Arthritis (RA) MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumato ...	Product Name: ocrelizumab Product Code: RO 496-4913/F03 INN or Proposed INN: ocrelizumab Other descript ...	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting			Female: yes Male: yes	1000	Phase 3	France;Greece;Spain;Belgium;Austria;Germany;United Kingdom